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Abstract
Microinvasive carcinomas and high-grade intraepithelial neoplasms are commonly discovered within the fallopian
tube of BRCA1 mutation carriers at the time of risk-reducing salpingo-oophorectomy, suggesting that many
BRCA1-mutated ovarian carcinomas originate in tubal epithelium. We hypothesized that changes in gene expression
profiles within the histologically normal fallopian tube epithelium of BRCA1mutation carriers would overlap with the
expression profiles in BRCA1-mutated ovarian carcinomas and represent a BRCA1 preneoplastic signature. Laser
capture microdissection of frozen sections was used to isolate neoplastic cells or histologically normal fallopian tube
epithelium, and expression profiles were generated on Affymetrix U133 Plus 2.0 gene expression arrays. Normal-risk
controls were 11 women wild type for BRCA1 and BRCA2 (WT-FT). WT-FT were compared with histologically nor-
mal fallopian tube epithelium from seven women with deleterious BRCA1 mutations who had foci of at least intra-
epithelial neoplasm within their fallopian tube (B1-FTocc). WT-FT samples were also compared with 12 BRCA1
ovarian carcinomas (B1-CA). The comparison of WT-FT versus B1-FTocc resulted in 152 differentially expressed
probe sets, and the comparison of WT-FT versus B1-CA resulted in 4079 differentially expressed probe sets. The
BRCA1 preneoplastic signature was composed of the overlap between these two lists, which included 41 concor-
dant probe sets. Genes in the BRCA1 preneoplastic signature included several known tumor suppressor genes such
as CDKN1C and EFEMP1 and several thought to be important in invasion and metastasis such as E2F3. The
expression of a subset of genes was validated with quantitative reverse transcription–polymerase chain reaction
and immunohistochemistry.
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Introduction
Ovarian carcinoma is the leading cause of death from gynecologic
malignant neoplasms in the developed world. Identification of the
early molecular events leading to ovarian carcinoma has been hindered
by the lack of an identifiable preneoplastic lesion and the limited oc-
currence of early-stage neoplasms. Although it has been proposed that
ovarian carcinoma originates from the surface epithelium of the ovary
and/or the epithelial lining of ovarian inclusion cysts, there have been
few reports of intraepithelial neoplasms at these sites [1,2].
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Alternatively, there has been increasing evidence that many ovarian
carcinomas originate within the fallopian tube [3]. Fallopian tube epi-
thelium can exhibit areas of increased proliferation and cytologic atypia,
called intraepithelial neoplasia (IEN). Most ovarian carcinomas are of
serous histology and frequently exhibit mutations in the critical cell
cycle regulator p53 [4]. Severe IEN in fallopian tubes has been found
in conjunction with mullerian malignant neoplasms, particularly serous
carcinomas of ovarian, uterine, or peritoneal origin [5,6]. Identical p53
mutations have been identified in tubal IEN and coexisting sporadic
serous carcinoma [7], suggesting that genetic disruption within the
fallopian tube may progress to ovarian carcinoma.
Further evidence for a tubal origin is suggested by the high preva-
lence of occult fallopian tube carcinomas identified among BRCA1
and BRCA2 mutation carriers undergoing risk-reducing salpingo-
oophorectomy (RRSO). Although the lifetime risk of ovarian carcinoma
in the general population is only 1% to 2%, women who inherit muta-
tions in the BRCA1 and BRCA2 genes have up to a 50% lifetime risk
of ovarian carcinoma [8]. These high-risk women are frequently dis-
covered to have occult neoplasms at the time of RRSO, and 57% to
100% of these lesions arise in the fallopian tube [9–11]. Fallopian tube
epithelium frequently contains areas that have been termed p53 foci
(also referred to as p53 signatures), which overexpress p53 and have in-
creased expression of the proliferation marker Ki-67 [12]. These tubal
p53 foci are more frequent in tubes from BRCA1 and BRCA2mutation
carriers compared with normal-risk women, and they have also been
shown to exhibit decreased expression of the tumor suppressor protein
p27 [13]. These observations have resulted in the proposal of a new
paradigm for ovarian carcinoma, in which the fallopian tube epithelium
acquires a sequence of molecular abnormalities leading to an in situ
or invasive neoplasm, which exfoliates and spreads to the ovary and
peritoneum [3]. Validating the role of the fallopian tube in ovarian
carcinoma carcinogenesis will require additional studies, such as com-
parative analysis of gene expression between wild-type and high-risk
fallopian tubes.
We obtained frozen fallopian tube tissue from seven women with
BRCA1 mutations found to have occult invasive carcinomas or severe
IEN in the fallopian tube on final pathologic examination. We hy-
pothesized that the histologically normal tubal epithelium from these
women would possess a gene expression profile that would reflect early
alterations in gene expression contributing to the development of car-
cinoma. By comparing the gene expression profiles between these
high-risk fallopian tubes and histologically normal fallopian tubes from
women with wild-type BRCA1 and BRCA2, we identified a set of
genes potentially important in the development of BRCA1-associated
carcinomas. We hypothesized that genes important in BRCA1 ovar-
ian carcinogenesis would have similarly altered expression patterns
in BRCA1 carcinomas. Therefore, we used the expression patterns in
BRCA1 ovarian carcinomas to further define the genes of interest in
BRCA1 tubal epithelium.
Materials and Methods
Study Design and Sample Selection
All tissues and clinical information were obtained from the Univer-
sity of Washington Gynecologic Oncology Tissue Bank according to
an institutional review board–approved protocol. To maximize the
likelihood of identifying biologically important gene differentially ex-
pressed between histologically normal BRCA wild-type fallopian tubes
and high-risk fallopian tubes from BRCA1 mutation carriers, we spe-
cifically selected BRCA1 mutation carriers possessing occult micro-
invasive or high-grade intraepithelial fallopian tube neoplasm to create
the gene profile (B1-FTocc). In addition, to minimize the false dis-
covery rate, we also identified genes differentially expressed between
the BRCA wild-type fallopian tube epithelium (WT-FT) and invasive
BRCA1 carcinomas (B1-CA).We limited ourBRCA1 preneoplastic pro-
file to genes showing concordant up-regulation or down-regulation in
both B1-FTocc and B1-CA. Thirty patients were analyzed to create
the BRCA1 preneoplastic gene signature: 11 histologically normal fallo-
pian tube epithelium from women with wild-type BRCA1 and BRCA2
(WT-FT), 7 histologically normal fallopian tube epithelium from
women with deleterious BRCA1 mutations and documented occult
microinvasive or high-grade intraepithelial fallopian tube carcinoma
(B1-FTocc), and 12 high-grade serous ovarian carcinomas from women
with deleterious BRCA1 mutations (B1-CA). The characteristics of
these patients are shown in Table 1.We choseWT-FTsamples to match
the age and menopausal distribution of the B1-FTocc cases. Some
women in the WT-FT group had a personal history of breast cancer
or a family history of breast cancer; however, women were excluded
from the WT-FT group if they had a family history of ovarian cancer.
All WT-FT control women had had full gene sequencing by Myriad
genetics, and those who did not have comprehensive rearrangement
testing performed by Myriad were screened with Multiplex Ligation–
dependentProbeAmplification (MRC-HollandBV,Amsterdam,Holland)
according to the manufacturer’s instructions in our laboratory using
normal DNA extracted from lymphocytes. For the B1-FTocc samples,
the histologically normal epithelium was obtained from the same fallo-
pian tube discovered to contain the occult fallopian tube neoplasm.
Three of the seven B1-FTocc women were premenopausal at the time
of oophorectomy.
Laser Capture Microdissection, RNA Amplification, and
Gene Expression Chips
Tissues samples had been collected at the time of RRSO or ovarian
carcinoma cytoreductive surgery and were immediately frozen in the
operating room in liquid nitrogen in Tissue-Tek OCT (Alphen aan
den Rijn, the Netherlands). For RRSO specimens, a small piece of
tubal fimbriae was collected for the tissue bank. A frozen section
of that tissue was stained with hematoxylin and eosin to confirm nor-
mal histologic diagnosis and rule out neoplasia in the research speci-
men. The remaining fallopian tube tissues from these cases were then
subjected to serial sectioning by the pathologist to look for intraepithe-
lial carcinoma or invasive carcinoma. All stored samples were subjected
to the identical protocol of laser capture microdissection (LCM), linear
RNA amplification, andmicroarray production.Hematoxylin and eosin
slides from the frozen tissue OCT blocks were reviewed to select
blocks with adequate distal fimbriated fallopian tube epithelium. Before
LCM, 7-μm frozen sections were cut, adhered onto glass membrane
slides (Arcturus, Mountain View, CA), and immediately stored on
dry ice. Before LCM, the slides were dehydrated and stained with
hematoxylin with the Histogene LCM Frozen Section Staining Kit
(Arcturus). Slides were immediately transferred to the Veritas Laser
Capture Microdissection system (Arcturus). Fallopian tube epithelium
from the distal fimbriated fallopian tube was selectively captured for
the fallopian tube samples, and ovarian carcinoma cells were selectively
captured for neoplastic samples (Figure W1). Total RNA was isolated,
and contaminating DNA was removed using the PicoPure RNA Isola-
tion Kit (Arcturus) as per the company’s protocol. The MessageAmp II
aRNA amplification Kit (Ambion, Austin, TX) was used to amplify
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the total RNA once. The quality of each amplified RNA sample was
confirmed using Agilent 2000 Bioanalyzer RNA 6000 Pico LabChip
Kit (Agilent Technologies, Inc, Santa Clara, CA), and quantity was
measured using a NanoDropND-1000 Spectrophotometer (NanoDrop
Technologies, Wilmington, DE). All labeling, hybridization, and scan-
ning were performed at the University of Washington Centre for Array
Technology core facility. Amplified complementary DNA (cDNA) was
purified, enzymatically fragmented, and labeled with biotin. Quality
and quantity of the purified labeled cDNA product were confirmed
before hybridizing to Affymetrix GeneChip U133A Plus 2.0 Arrays
(Affymetrix, Inc, Santa Clara, CA). To minimize batch effect, several
samples from each study group were included in each batch of array runs.
Development of the Gene Expression Profile
GeneSifter (Seattle, WA) software was used for pairwise gene expres-
sion analysis and clustering analysis (Manhattan, Complete Linkage).
For pairwise gene expression analysis, a Welch t test was used when gen-
erating P values. To develop a potential BRCA1 preneoplastic gene ex-
pression profile, two independent comparisons were made. First, the 11
WT-FTwere compared with the seven B1-FTocc samples, and probe
sets were selected, which showed a 1.8-fold differential expression at P <
.01. To minimize the false discovery rate, we also performed a compar-
ison between the 11 WT-FT and 12 B1-CA and selected probe sets,
which showed a 1.8-fold differential expression at P < .01. Probe sets
were only selected for the BRCA1 preneoplastic gene expression profile
if they demonstrated concordant up-regulation or down-regulation in
both the B1-FTocc and the B1-CA. The 1.8-fold was the cutoff at which
we had most overlapping genes while still optimizing the ratio of over-
lapping genes to nonoverlapping genes.
Real-time Quantitative Reverse Transcription–Polymerase
Chain Reaction Analysis
Real-time quantitative reverse transcription–polymerase chain reac-
tion (RT-PCR) was used to validate the Affymetrix array results for four
genes from the BRCA1 preneoplastic signature. For each group (WT-FT,
B1-FTocc, and B1-CA), five representative cases were selected and ana-
lyzed for expression of the four genes (EFEMP1, p57, CYP3A5, and
CSPG5). TaqManGeneExpressionAssays (AppliedBiosystems,Carlsbad,
CA) were used forEFEMP1 (Hs01013942_m1), p57 (Hs00908986_g1),
CYP3A5 (Hs02511768_s1), and CSPG5 (Hs00962721_m1), and
GAPDH was used as the reference gene. All samples were run in trip-
licate, and the comparative C t method was used for relative quantita-
tion using ABI PRISM Sequence Detection Software (Applied
Biosystems). Target gene C t values were normalized to GAPDH.
Interrogation of the BRCA1 Preneoplastic Gene Signature
Using Independent Samples
Additional fallopian tube samples that were not used to create the
gene expression signature were selected to interrogate the BRCA1 pre-
neoplastic gene signature. To test the intrasample reproducibility of the
tubal expression profiles, three duplicates of the B1-FTocc samples
were analyzed (Table W1). For two of these B1-FTocc – DUP cases
(B1-FTocc no. 2 – DUP and BT-FTocc no. 6 – DUP), expression
arrays were created using tissue from the fallopian tube contralateral
Table 1. Cases Used to Generate the BRCA1 Preneoplastic Gene Signature.
Case Identifier Age (years) Menopausal Status BRCA1/2 Status* Other Characteristics
WT-FT no. 1 46 Pre Negative Personal history of breast cancer
WT-FT no. 2 47 Post Negative Personal history of breast cancer
WT-FT no. 3 48 Post Negative Personal history of breast cancer
WT-FT no. 4 48 Pre Negative No personal history of cancer
WT-FT no. 5 49 Post Negative Personal history of breast cancer
WT-FT no. 6 50 Pre Negative Personal history of breast cancer
WT-FT no. 7 52 Pre Negative Personal history of breast cancer
WT-FT no. 8 54 Post Negative Personal history of breast cancer
WT-FT no. 9 55 Post Negative Personal history of breast DCIS
WT-FT no. 10 61 Post Negative No personal history of cancer
WT-FT no. 11 61 Post Negative Personal history of breast cancer
B1-FTocc no. 1 39 Pre B1.3109insAA Microinvasion left fallopian tube
B1-FTocc no. 2 40 Post B1.M1V (120A>G) Microinvasion left fallopian tube
B1-FTocc no. 3 47 Pre B1.2800delAA High-grade intraepithelial
B1-FTocc no. 4 49 Pre B1.3795del4 Microinvasion right fallopian tube†
B1-FTocc no. 5 53 Post B1.del ex14-20 High-grade intraepithelial
B1-FTocc no. 6 62 Post B1.C61G High-grade intraepithelial
B1-FTocc no. 7 63 Post B1.2800delAA Microinvasion left fallopian tube
B1-CA no. 1 40 Pre B1.2576.delC Stage IIIC, grade 3, serous carcinoma
B1-CA no. 2 41 Pre B1.185delAG Stage IIIC, grade 3, serous carcinoma
B1-CA no. 3 44 Pre B1.2798del4 Stage IIIC, grade 3, serous carcinoma
B1-CA no. 4 49 Pre B1.3795del4 Stage IIIC, grade 3, serous carcinoma†
B1-CA no. 5 50 Post B1.5382insC Stage IA, grade 3, undifferentiated
B1-CA no. 6 51 Post B1.3171ins5 Stage IIIC, grade 3, serous carcinoma
B1-CA no. 7 54 Post B1.2594delC Stage IV, grade 3, serous carcinoma
B1-CA no. 8 54 Post B1.del_exon14 Stage IIIC, grade 3, serous carcinoma
B1-CA no. 9 55 Post B1.M1V (120A>G) Stage IIC, grade 3, serous carcinoma
B1-CA no. 10 57 Post B1.5382insC Stage IIIC, grade 3, mixed serous/endo
B1-CA no. 11 57 Post B1.5382insC Stage IIIC, grade 3, serous carcinoma
B1-CA no. 12 65 Post B1.5382insC Stage IIIC, grade 3, serous carcinoma
*Negative cases were wild-type by full sequencing as well as by comprehensive testing for gene rearrangements. WT-FT indicates histologically normal fallopian tube epithelium from BRCA1 wild-type
patients; B1-FTocc, histologically normal fallopian tube epithelium from patients with deleterious BRCA1 mutations and at least high-grade intraepithelial fallopian tube neoplasm; B1-CA, tumor tissue
from patients with deleterious BRCA1 mutations.
†B1-FTocc no. 4 and B1-CA no. 4 are from the same individual who had both microscopic invasive neoplasm within the fallopian tube and peritoneal metastasis. DCIS indicates ductal carcinoma in situ.
Menstrual phase of WT-FT cases: WT-FT no. 1 and WT-FT no. 7 had proliferative endometrium and WT-FT no. 4 and WT-FT no. 6 did not have hysterectomy performed.
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to the microinvasive or high-grade intraepithelial lesion. For the dupli-
cate of B1-FTocc no. 1, LCMwas performed a second time using sepa-
rate sections obtained approximately 100 μm further into the frozen
tissue block. In addition, 12 BRCA1-mutated fallopian tubes from
postmenopausal women, which did not contain occult lesions (B1-
FT), were also analyzed (Table W2). The expression profiles were
generated by comparing to the same set of WT-FT cases. These addi-
tional expression profiles were then analyzed by combining them one
at a time with the original 30 samples that had been used to create
the premaligant gene signature. Unsupervised hierarchical clustering
(Manhattan, Complete Linkage) using the probe sets from the BRCA1
preneoplastic gene signature was performed for each combination to
determine whether the additional cases contained the BRCA1 pre-
neoplastic expression profile and would therefore cluster with the
B1-FTocc cases. In addition, for 10 of the B1-CA carcinomas with
adequate DNA available, DNA was sequenced for p53 exons 4 to 10
as previously described [14].
Ki-67 Immunohistochemistry
To validate the array gene expression data for MKI67 (antigen iden-
tified by monoclonal antibody Ki-67), we performed immunohisto-
chemistry on a larger set of fallopian tube samples, which had been
stored as paraffin blocks. Most of these cases had right and left distal
fallopian tube tissues available, and an average Ki-67 staining score was
obtained from both tubes. Fallopian tube tissues from 26 BRCA1 wild-
type cases were compared with fallopian tube tissues from 52 BRCA1
mutation carriers without carcinoma obtained at RRSO. Paraffin sec-
tions were deparaffinized and sequentially rehydrated, and endogenous
peroxidases were blocked. Heat-mediated antigen retrieval was per-
formed in a citrate buffer (Antigen Unmasking Solution; Vector Lab-
oratories, Burlingame, CA). Slides were incubated with the Ki-67
mousemonoclonal antibodyMIB-1, diluted 1:100 (Dako,Copenhagen,
Denmark). Sections were washed with phosphate-buffered saline and
incubated with secondary antibody (horseradish peroxidase–antimouse;
Vector Laboratories). DABwas used to visualize antibody complexes, and
sections were counterstained with hematoxylin. Negative and positive
controls were assessed for each run. Slides were scored by two indepen-
dent observers blinded to case designation. The percentages of positive
epithelial cells were scored (0 = none, 1 = 1%, 2 = 2%-4%, 3 = 5%-15%,
4 ≥15%). AMann-Whitney test was used to compare the staining results.
Results
Affymetrix Gene Expression
There were 18,600 probe sets expressed on the Affymetrix chips,
which showed quality more than 0.7 in all samples. There were
152 probe sets with significant differential expression (>1.8-fold, P <
.01) between the WT-FT and B1-FTocc. There were 4079 probe sets
with significant differential expression (>1.8-fold, P < .01) between the
WT-FT and B1-CA. The 152 probe sets differentially expressed from
the BI-FTocc were compared with the 4079 differentially expressed
probe sets in the B1-CA (Figure 1). The overlap between the two dif-
ferentially expressed probe sets consisted of 29 probe sets downregulated
in both groups, 12 probe sets upregulated in both groups, and 7 probe
sets showing contradictory expression (up-regulation in one comparison
and downregulated in the other). The 41 probe sets demonstrating
concordant up-regulation or down-regulation in both comparisons
comprised the BRCA1 preneoplastic gene signature and are shown in
Table 2 and Figure 2.
To test the significance of the overlap in differentially expressed genes,
we created a simulation in which there were 4079 randomly selected ex-
pressed clones in one group and 152 in a second group from 18,600 ex-
pressed clones and compared overlap. We repeated this simulation
10,000 times. A total of 21 overlapping clones were only observed in
1 (0.01%) of 10,000 simulations, and 22 ormore overlapping genes were
never observed. These data suggest that the overlap of 41 genes between
our BRCA1 tubal epithelium and BRCA1 carcinomas is highly signifi-
cant and that it did not occur by chance. The concordance of direction
of the expression differences in 41 (85%) of 48 overlapping probes also
suggests that overlap in differentially expressed genes is nonrandom.
Real-time Quantitative RT-PCR Analysis
Figure 3 shows the Affymetrix expression array results imposed be-
side the real-time quantitative RT-PCR results for each of the four se-
lected genes (EFEMP1, p57, CYP3A5, and CSPG5). For each gene, the
real-time quantitative RT-PCR shows a similar expression pattern to the
corresponding Affymetrix array.
Clustering Analysis
The 30 samples used to create the BRCA1 preneoplastic gene sig-
nature were subjected to unsupervised hierarchical clustering analysis
using all 18,600 probe sets expressed with quality greater than 0.7
(Figure W2). The B1-CA formed a distinct group, but the clustering
of the B1-FTocc and WT-FT did not generate any distinct pattern
using all expressed probe sets. Interestingly, using only the 41 overlapping
probes, the wild-type samples separated into distinct premenopausal
and postmenopausal groups, which they did not do when clustering
was based on the entire expressed probe set. Of 10 carcinomas evaluated,
6 contained a somatic p53 mutation determined by sequencing p53
exons 4 to 10 (data not shown). Carcinomas 2, 5, 6, 7, 10, and 11
had p53 mutations, whereas carcinomas 1, 3, 9, and 12 were wild-type.
The p53 mutation status was not associated with how the carcinomas
clustered when considering the 41 overlapping probe sets or all of the
18,600 expressed probes.
Figure 1. Diagram illustrating the protocol used to define the
BRCA1 preneoplastic gene signature: Pairwise comparison be-
tween the WT-FT group and the B1-FTocc group (fold change ≥
1.8, P < .01) identified 152 differentially expressed probe sets.
Pairwise comparison between the WT-FT group and the B1-CA
group (fold change ≥ 1.8, P < .01) identified 4079 differentially ex-
pressed probe sets. To minimize the false discovery rate, probe
sets were only included in the gene signature with concordant
down-regulation or up-regulation in both pairwise comparisons
(hatched region).
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The duplicated samples from the B1-FTocc group were then added to
the clustering analysis and subjected to unsupervised hierarchical cluster-
ing using the BRCA1 preneoplastic gene signature. As shown in
Figure W3, each of the duplicated samples clustered closely with their
paired sample even when obtained from the contralateral FT, demonstrat-
ing the reproducibility of the expression profile in independent experi-
ments as well as the consistency between paired bilateral fallopian tubes.
To further interrogate the BRCA1 preneoplastic gene signature,
expression profiles from 12 additional B1-FT that had not been used
in developing the expression profile were each individually combined
with the 30 samples used to create the signature and subjected to un-
supervised hierarchical clustering using the BRCA1 preneoplastic gene
signature. Five of the new samples clustered with the B1-FTocc/B1-CA
group, whereas seven of the new samples clustered with the WT-FT
(Table W2). A representative example of each clustering pattern is
shown in Figure W4. This suggested that 5 (42%) of the 12 B1-FT
had experienced sufficient molecular disruptions to resemble B1-FTocc
or B1-CA samples. Although the remaining seven B1-FT test samples
clustered with wild-type fallopian tubes, they always clustered with the
group from premenopausal women.
Ki-67 Immunohistochemistry
The Affymetrix array analysis showed a significantly increased expres-
sion ofMKI67 (gene for the antigen identified by monoclonal antibody
Ki-67) in the B1-FTocc compared withWT-FT (P = .01; Figure 4A). To
confirm the generalizability of the preneoplastic expression pattern in a
larger set of wild-type and BRCA1 histologically normal FT, we evalu-
ated Ki-67 protein expression by immunohistochemistry in a larger set of
paraffin-embedded FT specimens. Significantly higher Ki-67 protein
expressionwas identified in fallopian tubes fromBRCA1mutation carriers
than from BRCA1wild-type women (P = .0002) who did not have cancer
(Figure 4B ). Representative images of low Ki-67 staining in WT-FT
(Figure 4C ) and high Ki-67 staining in B1-FT (Figure 4D) are shown.
Discussion
For many years, it was believed that ovarian carcinoma arises from the
ovarian surface epithelium or in cortical inclusion cysts in the ovary. In
accordance with this belief, most studies assessing disruption of gene
expression in ovarian carcinomas have focused on the ovarian surface
epithelium and carcinomas within the ovarian tissue [15]. However,
Table 2. The 41 Probe Sets Demonstrating Concordant Up-regulation or Down-regulation in Both Comparisons between WT-FT and B1-FTocc or B1-CA.
Affymetrix Probe Set Gene Name Gene Symbol WT-FT vs B1-FTocc WT-FT vs B1-CA
Fold P Fold P
Downregulated
230130_at Transcribed locus Unknown 3.7 .0020 3.4 .0054
214078_at Primary neuroblastoma cDNA Unknown 3.6 .0003 7.4 .0001
201843_s_at EGF-containing fibulin-like extracellular matrix protein 1 EFEMP1 3.4 .0015 12.4 .0001
205568_at Aquaporin 9 AQP9 2.7 .0021 3.4 .0020
214235_at Cytochrome P450, family 3, subfamily A CYP3A5 2.7 .0048 5.2 .0023
226228_at Aquaporin 4 AQP4 2.6 .0081 7.7 .0003
213182_x_at Cyclin-dependent kinase inhibitor 1C (p57, Kip2) CDKN1C 2.5 .0008 3.1 .0014
203710_at Inositol 1,4,5-triphosphate receptor, type 1 ITPR1 2.4 .0004 3.7 .0002
214607_at p21 (CDKN1A)-activated kinase 3 PAK3 2.4 .0070 5.8 .0002
231183_s_at Jagged 1 (Alagille syndrome) JAG1 2.3 .0002 1.9 .0011
218656_s_at Lipoma HMGIC fusion partner LHFP 2.3 .0032 2.8 .0083
218717_s_at Leprecan-like 1 LEPREL1 2.3 .0034 2.9 .0034
229480_at MRNA; cDNA DKFZp686I18116 Unknown 2.1 .0018 2.2 .0002
209506_s_at Nuclear receptor subfamily 2, group F, member 1 NR2F1 2.1 .0036 7.5 .0000
231262_at Transcribed locus Unknown 2.1 .0035 3.0 .0088
201497_x_at Myosin, heavy chain 11, smooth muscle MYH11 2.1 .0068 15.5 .0000
236277_at Primary neuroblastoma cDNA Unknown 2.0 .0094 3.5 .0001
201885_s_at Cytochrome b5 reductase 3 CYB5R3 2.0 .0004 1.8 .0066
230233_at Transcribed locus Unknown 2.0 .0047 1.9 .0073
1557866_at Chromosome 9 open reading frame 117 C9orf117 2.0 .0013 6.0 .0001
201162_at Insulin-like growth factor binding protein 7 IGFBP7 2.0 .0088 6.1 .0000
201427_s_at Selenoprotein P, plasma, 1 SEPP1 2.0 .0004 2.3 .0010
213451_x_at Transcribed locus, sim to tenascin XB isoform 1 TNXB 1.9 .0072 5.3 .0002
218087_s_at Sorbin and SH3 domain containing 1 SORBS1 1.9 .0082 2.1 .0038
204235_s_at GULP, engulfment adaptor PTB domain containing 1 GULP1 1.9 .0006 4.8 .0000
218718_at Platelet-derived growth factor C PDGFC 1.9 .0007 1.8 .0059
209575_at Interleukin 10 receptor, beta IL10RB 1.9 .0010 1.8 .0016
209505_at Nuclear receptor subfamily 2, group F, member 1 NR2F1 1.8 .0096 7.0 .0000
37005_at Neuroblastoma, suppression of tumorigenicity 1 NBL1 1.8 .0066 2.5 .0017
Upregulated
225857_s_at Hypothetical LOC388796 LOC388796 2.4 .0000 2.6 .0000
238482_at Kruppel-like factor 7 (ubiquitous) KLF7 2.4 .0020 2.2 .0050
39966_at Chondroitin sulfate proteoglycan 5 CSPG5 2.1 .0030 6.2 .0000
203693_s_at E2F transcription factor 3 E2F3 2.1 .0054 6.4 .0000
1560622_at CDNA FLJ20196 fis, clone COLF0944 Unknown 2.0 .0038 2.2 .0005
201577_at Nonmetastatic cells 1, protein (NM23A) NME1 1.9 .0066 3.0 .0002
65588_at Hypothetical LOC388796 LOC388796 1.9 .0000 2.3 .0001
224474_x_at SMEK homolog 2, suppressor of mek1 SMEK2 1.9 .0087 2.0 .0037
212020_s_at Antigen identified by monoclonal antibody Ki-67 MKI67 1.9 .0056 3.5 .0000
224623_at Transcribed locus, similar THO complex 3 THOC3 1.8 .0003 3.2 .0000
1560258_a_at Homo sapiens, clone IMAGE:5590287, mRNA Unknown 1.8 .0044 3.0 .0000
216262_s_at TGFB-induced factor homeobox 2 TGIF2 1.8 .0094 1.8 .0033
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the relevance of the ovarian surface epithelium has come under increas-
ing scrutiny, and a comprehensive review of the literature regarding
the origin of ovarian carcinoma concluded that there is insufficient
evidence to support ovarian surface epithelium or inclusion glands as
the origin of ovarian carcinomas [16]. In contrast, there has been in-
creasing evidence that many ovarian and primary peritoneal carcinomas
arise from neoplastic alterations within the fallopian tube epithelium.
This view has been supported by the frequent discovery of occult fal-
lopian tube neoplasms in fallopian tubes removed prophylactically
from women at high risk due to hereditary BRCA1 or BRCA2 muta-
tions [9–11]. The tubal epithelium in women with BRCA1 mutations
who have up to a 50% lifetime risk of ovarian carcinoma could repre-
sent a unique opportunity to study at-risk tissues just before neoplastic
transformation. We hypothesized that the epithelium in these high-risk
fallopian tubes would express some of the earliest gene disruptions
leading to ovarian carcinoma.
Half of all BRCA1 mutation carriers never develop ovarian carci-
noma. This fact could make it difficult to identify a BRCA1 preneo-
plastic gene expression profile in normal BRCA1 tubal epithelium in
cancer-free BRCA1 mutation carriers. Our current study is unique be-
cause we used histologically normal fallopian tube epithelium from the
same fallopian tubes that contained at least a high-grade intraepithelial
neoplasm. By using tissues already proven susceptible to neoplastic trans-
formation, we improved our ability to identify a BRCA1 preneoplastic
expression profile in BRCA1 mutation carriers. We predicted that gene
expression differences that precede morphologically identifiable neo-
plastic transformation should also be present in BRCA1-associated ovar-
ian carcinomas. Indeed, 41 of 152 differentially expressed probe sets in
Figure 2. The 41 probe sets in the BRCA1 preneoplastic profile include several known tumor suppressors and oncogenes.
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the normal tubal epithelium from BRCA1 mutation carriers with tubal
neoplasia were also similarly differentially expressed in the BRCA1 carci-
nomas when compared with tubal epithelium from normal-risk women.
Our computer model confirmed that the identified overlap in expres-
sion profiles between BRCA1 tubal epithelium and BRCA1 carcinoma
is highly significant, suggesting that the expression profile that we termed
the BRCA1 preneoplastic signature represents a true biological phenome-
non. The 41 overlapping probe sets represent unique genes altered in
Figure 4. Validation of MIK67 expression data with Ki-67 immunohistochemistry in 26 WT-FT and 52 B1-FT. (A) MIK67 gene expression in
the 11 WT-FT samples compared with the 7 B1-FTocc samples (P = .01). (B) Ki-67 protein expression (brown) in the fallopian tubes from
26 wild-type women compared with fallopian tubes from 52 women with deleterious BRCA1mutations (P= .0002). Representative images
of low Ki-67 expression in a wild-type case (C) and high Ki-67 staining in a BRCA1-mutated case (D).
Figure 3. Correlation between expression array and real-time quantitative RT-PCR results: Four genes from the gene signature were
selected for validation by RT-PCR with TaqMan assays. Five cases were used from each group (WT-FT, B1-FTocc, and B1-CA). The four
genes included EFEMP1 (EGF-containing fibulin-like extracellular matrix protein 1), CDKN1C (cyclin-dependent kinase inhibitor 1C or
p57), CYP3A5 (cytochrome P450, family 3, subfamily A), and CSPG5 (chondroitin sulfate proteoglycan 5 or neuroglycan C). For each
gene, the array expression data are shown beside the corresponding RT-PCR results.
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progression from normal fallopian tube epithelium to carcinoma. Fur-
thermore, many of these 41 probe sets represent genes that have been
shown to play an important role in cancer biology, such as EFEMP1,
CYP3A5, CDKN1C, NR2F1, E2F3,MKI67, NME1, and CSPG5.
One gene in the BRCA1 preneoplastic signature overexpressed in
BRCA1 FT is the gene encoding the Ki-67 antigen, expressed in the
nuclei of proliferating cells. To generalize our findings to other cases
from women with known BRCA1 mutations, we performed immuno-
histochemistry in a larger series of normal FTs. Consistent with the
array data, our pathologists (who were blinded to case designation)
identified significantly higher Ki-67 protein expression in FT epithe-
lium of women with BRCA1 mutations compared to women with
negative genetic testing (Figure 4). These data suggest that at least some
elements of the BRCA1 preneoplastic signature are generalizable to
BRCA1-mutated FTs without neoplasia. These data suggest that before
neoplastic transformation, there exists a higher rate of proliferation in
BRCA1 tubal epithelium, which could increase the opportunity for
somatic clonal genetic changes (such as loss of the wild-type allele)
and subsequent neoplastic development.
Examples of downregulated probe sets in the BRCA1 preneoplastic
signature include those representing EFEMP1, CDKN1C, andNR2F1.
Decreased expression of each of these genes has been implicated in car-
cinogenesis in a variety of neoplasms. EFEMP1 (FLBN3) is a member
of the fibulin family, a family of secreted glycoproteins with repeated
epidermal growth factor domains and a unique C-terminal fibulin-type
module. Fibulins mediate cell-to-cell and cell-to-matrix communica-
tion within the extracellular matrix [17]. Mutations in EFEMP1 cause
an autosomal-dominant disorder associated with early onset macular
degeneration (Doyne honeycomb retinal dystrophy), which has been as-
sociated with excessive angiogenesis [18]. EFEMP1 has antiangiogenic
properties and has been shown to inhibit tumor growth in mice. The
expression of EFEMP1 is reduced in many human neoplasms, includ-
ing ovarian carcinoma [19], and EFEMP1 is inactivated by promoter
methylation in 38% of primary lung carcinomas but not in paired
normal lung tissue [20]. The cell cycle regulatory gene CDKN1C
(p57/Kip2) is an imprinted maternally expressed gene on chromosome
11p15.4. Disruption of CDKN1C expression causes the cancer pre-
disposing Beckwith-Wiedemann syndrome [21]. CDKN1C has also
been implicated as a tumor suppressor gene in a number of human
malignant neoplasms including breast, lung, pancreatic, bladder, esopha-
geal, and a variety of hematological and myeloid neoplasms [22,23].
Prostate explants from a CDKN1C knockout mouse develop IEN
and prostate adenocarcinoma in nude mice, providing the first mouse
model that is pathologically identical to human prostate carcinoma
[24]. CDKN1C dysregulation has not been extensively studied in ovar-
ian carcinoma, but the majority (75%) of sporadic ovarian carcinomas
demonstrate reduced CDKN1C protein expression (<10% of tumor
cells) using immunohistochemistry [25].NR2F1 encodes for the protein
chicken ovalbumin upstream promoter transcription factor I (COUP-
TF1). COUP-TF1 is a nuclear receptor that has been shown to repress
transcription, influence the tumor necrosis factor α signaling pathway
[26], and modulate the retinoic acid receptor [27]. In breast carcinoma,
decreased expression of COUP-TF1 is associated with the up-regulation
of aromatase expression [28]. Decreased expression of COUP-TF1 has
also been observed in ovarian and bladder carcinomas [29,30].
Upregulated probe sets in our BRCA1 preneoplastic signature in-
cluded E2F3, NME1, CSPG5, and MKI67. The E2F3 gene is a tran-
scription factor that has been implicated in malignant transformation
of human lung [31], prostate [32], and bladder carcinomas [33]. Up-
regulation of E2F transcription factors has been shown to influence
disruptions of the cell cycle in high-grade serous ovarian carcinomas
[34], and E2F3 has been used as a biomarker for ovarian carcinoma
[35]. The E2F3–Aurora-A axis has been implicated in colorectal can-
cer [36] and ovarian cancer [37], and recently, E2F3 has been impli-
cated in the proliferation of ovarian cancer cells through interaction
with epidermal growth factor receptor [38]. NME1 (NM23) over-
expression has been associated with decreased overall survival in pa-
tients with serous ovarian carcinoma [39]. CSPG5 (neuroglycan C,
neuregulin-6) is a growth factor that transactivates the ErbB2 (HER2/
neu) oncogene. CSPG5 is a membrane-anchored chondroitin sulfate
proteoglycan that stimulates cell proliferation in a dose-dependent fash-
ion, acts as a specific ligand for ErbB3, and is capable of transactivation
of ErbB2 (HER2) [40]. ErbB2 (HER2/neu) is a well-recognized onco-
gene capable of inducing cellular proliferation and disrupting epithelial
cellular polarity. Although CSPG5 has not been well studied in human
malignant neoplasms, CSPG5 is secreted by neural stem cells, and it
promotes its own proliferation in the fetal brain [41].
The traditional clonal model of carcinogenesis states that clonal
expansion and neoplastic proliferation stem from genetic disruptions
within an individual cell. However, a more contemporary hypothesis
called the epigenetic progenitor model proposes that before this clonal
event, there are global epigenetic alterations in nonneoplastic cell lines
that allow the proliferation of cell line–specific stem or progenitor cells.
This results in a large population of epigenetically disrupted progenitor
cells that could then be affected by an initiating mutation of a key
gatekeeper gene in a single cell [42]. An epigenetic progenitor model
could explain our ability to identify global alterations of gene expres-
sion of key tumor progenitor genes in at-risk epithelium in areas that
do not have histologically identifiable neoplastic proliferation. Further
epigenetic studies will be necessary to assess this hypothesis in BRCA1
tubal epithelium.
We assessed whether the tubal expression profile was consistent
between various areas of the distal FT by performing unsupervised
hierarchical clustering using independent samples from three of the
B1-FTocc cases (two from the contralateral tube). Regardless of whether
the duplicated samples were created from the ipsilateral or contralateral
fallopian tube, all three duplicates clustered immediately adjacent to
their corresponding sample when considering the preneoplastic gene
signature (Figure W3). This suggests that the gene disruptions we ob-
served in high-risk fallopian tubes represent a global field effect that
affects bilateral fallopian tubes in patients with BRCA1 mutations.
p53-immunopositive foci have been frequently observed in tubal
epithelium of both high-risk and normal-risk women [3,13]. We made
no effort to select p53-positive cells to derive the BRCA1 preneoplastic
expression profile. The resulting expression profile did not seem to
be driven by p53 because the expression profiles from the p53 wild-type
carcinomas were not distinct from the p53 mutant carcinomas when
just considering these genes. The probe sets on the Affymetrix array
representing p53 showed minimal signal regardless of BRCA1 status.
This is not surprising because p53 foci are generally small, occurring
in as few as 10 cells and, consequently, would only be present in a small
fraction of the cells that we used for expression array analysis. p53 foci
likely represent a clonal event (somatic mutation) in a small subset of
tubal epithelial cells. The fact that we can detect differences in ex-
pression profiles of BRCA1 tubal epithelium despite not selecting for
p53 foci implies that global alterations in gene expression including
MKI67 (Ki-67 protein) occur even in cells that do not have p53 altera-
tions or mutation. These data support an alternate model in which
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global alterations (including increased Ki-67) precede somatic clonal
events such as p53 mutation in p53 foci [13].
Three of the seven B1-FTocc samples available from our tissue bank
were collected from premenopausal women. To equalize the menopausal
status in our three groups, we specifically included cases in the WT-FT
and B1-CA groups that were premenopausal at the time of surgery.
When unsupervised hierarchical clustering was performed using the pre-
neoplastic gene signature, the four premenopausal WT-FT cases formed
a distinct group from the seven postmenopausal WT-FT cases. Inter-
estingly, when the 12 additional FT-B1 samples (which were all post-
menopausal) were subjected to clustering analysis, the 7 samples that
clustered with the WT-FT group always clustered with the premeno-
pausal WT-FT. It seems that BRCA1-mutated fallopian tubes maintain
a gene expression profile that is more similar to premenopausal tissue,
even without the stimulation of the premenopausal hormonal milieu.
Our group has recently demonstrated that proliferation in WT-FT as
measured by Ki-67 protein expression decreases with age, but Ki-67 ex-
pression is maintained at a higher level with a less marked decrease with
age in women with BRCA1 mutation [13]. Therefore, both protein ex-
pression and expression profiling suggest that BRCA1 fallopian tube
epithelium maintains a premenopausal proliferative phenotype. Overall,
5 (42%) of the 12 additional B1-FT samples clustered with the B1-
FTocc/B1-CA group based on the BRCA1 preneoplastic signature. This
closely reflects the percentage of women with BRCA1 mutations who
will go on to develop ovarian carcinoma [8]. Interestingly, the samples that
clustered with the B1-FTocc/B1-CA group had higher Ki-67 staining.
There has only been one published study by Tone et al. [43] looking at
differential gene expression profiles from BRCA1-mutated fallopian tube
epithelium and fallopian tube/ovarian carcinomas, which was designed
differently from our study. These investigators analyzed fallopian tube
epithelium only from premenopausal women, included both BRCA1
and BRCA2 mutation carriers, and focused on fallopian tubes without
associated carcinoma, as opposed to our strategy of microdissecting
epithelium from fallopian tubes containing at least high-grade intra-
epithelial neoplasm. Furthermore, their carcinoma group included
sporadic fallopian tube and ovarian carcinomas, whereas we compared
expression profiles specifically to BRCA1-mutated carcinomas. We felt
it was important to separate BRCA1 from BRCA2 fallopian tube epi-
thelium given that ovarian carcinomas have distinct different expression
profiles according to whether they have a BRCA1 or BRCA2 mutation
[44]. They observed that BRCA1-mutated fallopian tubes collected
during the luteal phase of the menstrual cycle were more likely to cluster
with the carcinoma samples. They hypothesized that the hormonal
environment of the luteal phase causes distinct changes in high-risk
fallopian tubes resulting in similar gene expression to carcinoma tissue.
Because of the different approaches between this study and our current
study, it is difficult to compare the specific genes identified. However,
both studies suggest that fallopian tube epithelium from BRCA1 muta-
tion carriers is susceptible to disruption in gene expression, which causes
histologically normal fallopian tube tissue to exhibit gene expression
resembling carcinoma.
By analyzing gene expression from histologically normal fallopian
tube epithelium isolated from BRCA1-mutated fallopian tubes contain-
ing early neoplasms, we have identified a potential BRCA1 preneoplastic
gene expression signature for BRCA1 serous carcinoma. This gene sig-
nature may include some of the earliest disruptions in gene expression
leading to the development of serous ovarian carcinoma. Further valida-
tion will be necessary to determine which of the genes from this signa-
ture are critical in this process and to identify the mechanisms of gene
expression alterations. The fact that these genes are disrupted in the
fallopian tube tissue before the development of invasive carcinoma
could make them useful targets for chemoprevention or early detection
of ovarian carcinoma.
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Figure W1. Illustration of LCM. (A) Fallopian tube tissue: (1) fixed slide immediately before performing LCM, (2) slide after LCM and
removal of tissue, (3) fallopian tube epithelial tissue adherent to collection cap, and (4) collection cap coated with fallopian tube epithelial
tissue at completion. (B) Tumor tissue: same steps (1-4) are shown.
Table W1. Duplicated Samples Used to Interrogate the Gene Expression Signature.
Unique Identifier Corresponding Case Tissue Block Used for LCM BRCA1 Status Menopausal Status
B1-FTocc no. 1 – DUP B1-FTocc no. 1 Ipsilateral FT B1.3109insAA Pre
B1-FTocc no. 2 – DUP B1-FTocc no. 2 Contralateral FT (120A>G) Post
B1-FTocc no. 6 – DUP B1-FTocc no. 6 Contralateral FT B1.C61G Post
For each of these patients, an independent section of fallopian tube was subjected to RNA isolation, amplification, and array creation.
Table W2. Twelve Additional Fallopian Tube Samples Used to Interrogate the BRCA1 Preneoplastic
Gene Signature.
Case Identifier Age (years) Menopausal Status BRCA1 Status Clustering Group
B1-FT no. 1 39 Post B1.IVS5-11 T>G WT-FT
B1-FT no. 2 43 Post B1.C61G WT-FT
B1-FT no. 3 45 Post B1.5677insA B1-FTocc
B1-FT no. 4 46 Post B1.13+1 G to A WT-FT
B1-FT no. 5 48 Post B1.975delAG WT-FT
B1-FT no. 6 49 Post B1.3124delA B1-FTocc
B1-FT no. 7 50 Post B1.3878insT WT-FT
B1-FT no. 8 51 Post B1.Q1200X B1-FTocc
B1-FT no. 9 52 Post B1.120A>G(M1V) B1-FTocc
B1-FT no. 10 53 Post B1.5385insC WT-FT
B1-FT no. 11 59 Post B1.del exon 17 B1-FTocc
B1-FT no. 12 62 Post B1.R1699W WT-FT
Each fallopian tube was collected at the time of prophylactic salpingo-oophorectomy from a patient
with a known deleterious BRCA1 mutations. None of these samples were used in the derivation of
the BRCA1 preneoplastic gene signature.
Figure W2. Unsupervised hierarchical clustering of cases using all
18,600 probe sets expressed with adequate quality on the arrays.
B1-CA formed a distinct group from the fallopian tube samples.
Figure W3. Using the same cases analyzed to create the gene signa-
ture, duplicate sections were made, and the protocol was repeated
to assess validity. For case no. 1, the ipsilateral FT was used, and
for case nos. 2 and 6, the contralateral FT was used. Frozen tissue
was subjected independently to sectioning, LCM, andRNA amplifica-
tion. These duplicated samples were then subjected to unsupervised
hierarchical clustering using the original 41 probe set gene signature.
Clustering of the three duplicated samples (B1-FTocc DUP) shows
that duplicates cluster near regardless ofwhether they are taken from
the ipsilateral or contralateral fallopian tube.
Figure W4. Representative examples of clustering with the independent B1-FT test samples using the 41 probe set gene signature.
(A) B1-FT no. 8 clustered with the B1-FTocc/B1-CA group, whereas (B) B1-FT no. 7 clustered with the WT-FT group.
